Neuroleptic-induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia

European Psychiatry

Volumn 14, Issue 2, 1999, Pages 84-88

  Krausz, M ^a   Moritz, S H ^a   Naber, D ^a   Lambert, M ^a   Andresen, B ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cognition; Extrapyramidal symptoms; Neuropsychology; Side effects

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOTHERAPY; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0033118149     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(99)80722-6     Document Type: Article

References (31)

1. Alexander GE, De Long MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-81.
2. Brekke JS, Raine A, Ansel M, Lencz T, Bird L. Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Schizophr Bull 1997; 23: 19-28.
3. Brown KW, White T. The psychological consequences of tardive dyskinesia. The effect of drug-induced parkinsonism and the topography of the dyskinetic movements. Br J Psychiatry 1991; 159: 399-403.
4. Brown KW, White T, Palmer D. Movement disorders and psychological tests of frontal lobe function in schizophrenic patients. Psychol Med 1992; 22: 69-77.
5. Brown KW, White T. The influence of topography on the cognitive and psychopathological effects of tardive dykinesia. Am J Psychiatry 1992; 149: 1385-9.
6. Collegium Internationale Psychiatriae Scalarum. Internationale Skalen für Psychiatrie, Weinheim: Beltz; 1991.
7. Courchesne E, Townshend J, Akshoomoff NA, Saitoh O, Yeung-Courehesne R, Lincoln A, et al. Impairment in shifting attention in autistic and cerebellar patients. Behav Neurosci 1994; 108: 848-65.
8. Crane GE, Naranjo ER, Chase C. Motor disorders induced by neuroleptics. A proposed new classification. Arch Gen Psychiatry 1971; 24: 179-84.
9. Cuesta MJ, Peralta V, Juan JA. Abnormal subjective experiences in schizophrenia: its relationships with neuropsychological disturbances and frontal signs. Eur Arch Psychiatry Clin Neurosci 1996; 246: 101-5.
10. Dech H, Northoff G. Zur Symptomatologie der Akathisie, Fortschritte Neurol Psychiatrie 1997; 65: 232-6.
11. Durwen HF, Calabrese P, Holinka B, Markowitsch HJ, Gehlen W. Neuropsychologische Aspekte bei idiopathischem Morbus Parkinson. Fortschr Neurol Psychiatrie 1995; 63: 68-71.
12. Fiez JA. Cerebellar contributions to cognition. Neuron 1996; 16: 13-5.
13. Frith CD, Bloxham CA, Carpenter KN. Impairments in the learning and performance of a new manual skill in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1986; 49: 661-8.
14. Gardos G, Casey DE, Cole JO, Perenyi A, Kocsis E, Arato M, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151: 836-41.
15. Goldberg TE, Weinberger DR. Effects of neuroleptic medication on the cognition of patients with schizophrenia: a review of recent studies. J Clin Psychiatry 1996; 57 Suppl 9: 62-5.
16. Gotham AM, Brown RG, Marsden CD. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988; 111: 299-321.
17. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-30.
18. Jahn T, Mussgay L. Die statistische Kontrolle möglicher Medikamenteneinflüsse in experimentalpsychologischen Schizophreniestudien: Ein Vorschlag zur Berechnung von Chlorpromazinäquivalenten. Z Klin Psychol 1989; 18: 257-67.
19. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988; 8 Suppl: 31-7.
20. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983; 106: 257-70.
21. Markowitsch HJ. Neuropsychologie des Gedächtnisses. Göttingen: Hogrefe; 1992.
22. Martin P, Albers M. Cerebellum and schizophrenia: a selective review. Schizophr Bull 1995; 21: 241-50.
23. Moritz S, Naber D, Krausz M, Lambert M, Andresen B. Neurokognitive Veränderungen in der Behandlung schizophrener Patienten unter Clozapin. In: Naber D, Müller-Spahn F, eds. Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums. Berlin: Springer; 1999. p. 90-108.
24. Simpson GM, Angus JWS. A rating scale for extrapyramidalside effects. Acta Psychiatr Scand 1970; 212 Suppl: 11-9.
25. Süllwold L. Die Selbstwahrnehmung defizitärer Störungen: Psychologische Aspekte des Basisstörungskonzeptes. In: Süllwold L, Huber G, eds. Schizophrene Basisstörungen. Berlin: Springer; 1986. p. 1-38.
26. Süllwold L. Manual zum Frankfurter Beschwerde-Fragebogen (FBF). Berlin: Springer; 1991.
27. Thomas P, McGuire R. Orofacial dyskinesia, cognitive function and medication. Br J Psychiatry 1986; 149: 216-20.
28. Wegner JT, Kane JM, Weinhold P, Woerner M, Kinon B, Lieberman J. Cognitive impairment in tardive dyskinesia. Psychiatry Res 1985; 16: 331-7.
29. World Health Organisation. SCAN - Schedules for Clinical Assessment in Neuropsychiatry. Genf: World Health Organization, Division of Mental Health, 1992.
30. Williams RM, Alagaratnam W, Hemsley DR. Relationship between subjective self-report of cognitive dysfunction and objective information-processing performance in a group of hospitalized schizophrenic patients. Eur Arch Psychiatry Neurol Sci 1984; 234: 48-53.
31. Zerssen Dv. Paranoid-Depressivitäts-Skala. Manual. Weinheim: Beltz; 1976.